Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE study

In this real-world Italian cohort, benralizumab was associated with rapid and sustained clinical remission in patients with SEA over 24 months. The high remission rates observed early and maintained throughout treatment support the role of benralizumab as a disease-modifying therapy and reinforce clinical remission as a meaningful therapeutic goal in SEA.

Authors

Institutions

Publication Details

Journal
World Allergy Organization Journal
Published
2026-01-14
DOI
https://doi.org/10.1016/j.waojou.2025.101159
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE study

Elena Altieri, Maria Filomena Caiaffa, Maria Aliani, G Pelaia et al.
World Allergy Organization Journal
Asthma and respiratory diseases
article

Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE study

Elena Altieri, Maria Filomena Caiaffa, Maria Aliani, G Pelaia, Paola Paola Rogliani, Pietro Schino, Micaela Romagnoli, Pietro Bracciale, A Vultaggio, Marco Caminati, Giorgio Walter Canonica, Gianenrico Senna, Laura Malerba, Paolo CAMELI, L Brussino, J W V Schroeder, Stefano Del Giacco, Maria D'Amato, Cristiano Caruso
article en

Abstract

In this real-world Italian cohort, benralizumab was associated with rapid and sustained clinical remission in patients with SEA over 24 months. The high remission rates observed early and maintained throughout treatment support the role of benralizumab as a disease-modifying therapy and reinforce clinical remission as a meaningful therapeutic goal in SEA.

World Allergy Organization JournalVol. 19(2)
University of Siena (IT), University of Foggia (IT), University of Rome Tor Vergata (IT), University of Verona (IT), Humanitas University (IT), University of Cagliari (IT), University of Milan (IT), Agostino Gemelli University Polyclinic (IT), Magna Graecia University (IT), Ospedale Antonio Cardarelli (IT), Istituti Clinici Scientifici Maugeri (IT), Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT), AULSS 2 Marca Trevigiana (IT), Ospedale Papa Giovanni XXIII (IT), Casa di Cura Villa Garda (IT), Ospedale San Paolo (IT), A. O. Ordine Mauriziano di Torino (IT), Policlinico Tor Vergata (IT), AstraZeneca (Italy) (IT), Ospedale Monaldi (IT), Ospedale Generale Regionale Francesco Miulli (IT), Ospedale SS. Annunziata (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), IRCCS Humanitas Research Hospital (IT), Ospedale Santa Corona (IT), University of Florence (IT)
AstraZeneca
Life below water
Openalex Percentile: Top 90%
Asthma and respiratory diseases
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.